查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1924690

大容量注射剂市场按产品类型、包装、最终用户、应用和分销管道划分－2026-2032年全球预测

Large Volume Parenteral Market by Product Type, Packaging, End User, Application, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，大容量注射剂市场价值将达到 37.4 亿美元，到 2026 年将成长至 39.9 亿美元，年复合成长率为 7.74%，到 2032 年将达到 63 亿美元。

关键市场统计数据
基准年 2025 37.4亿美元
预计年份：2026年 39.9亿美元
预测年份 2032 63亿美元
复合年增长率 (%) 7.74%

大剂量注射疗法的策略实施：临床影响、供应链复杂性以及塑造医疗服务提供的技术和监管演变框架

大容量肠外营养疗法仍是急性慢性治疗路径中的重要组成部分，为维持体液平衡、血流动力学稳定、药物输注和营养支持提供关键支持。临床需求广泛，涵盖围手术全期管理和重症监护復苏，以及门诊静脉输液和长期经肠营养。在此背景下，临床最佳实践、不断变化的医疗环境和不断发展的生产标准相互作用，造就了复杂的产业格局。

识别将改变临床实践、生产模式和供应链韧性的关键转折点，从而在全球范围内重新定义大容量注射剂领域。

大容量注射剂领域正经历着变革性的转变，影响着临床实务、生产结构和商业模式。在临床方面，护理路径正显着地向以患者为中心的模式转变，优先考虑门诊给药、短期住院和家庭输注方案。这种转变迫使生产者和医疗服务提供者调整配方、包装和使用说明，以支持在传统急诊环境之外的安全给药。

评估2025年美国关税调整对采购、生产奖励、成本结构和策略供应链重组的累积影响

近期主要经济体采取的关税措施对大剂量注射剂产业的筹资策略、供应商选择和生产经济效益产生了连锁反应。关税相关的成本压力促使相关人员重新评估其全球采购基础，提高关键部件的本地化程度，并重新谈判供应商合同，以降低原材料价格波动带来的风险。为此，许多企业正在调整库存缓衝，并采取近岸外包策略，以减少跨国政策波动带来的风险。

提供可操作的细分洞察，揭示产品类型、最终用户、包装形式、应用和分销管道如何相互作用，从而推动临床和商业性优先事项的发展。

细緻的市场区隔观点揭示了产品属性、临床环境、包装、临床应用和通路如何共同影响采购和临床决策。从产品类型来看，市场可分为胶体和晶体。胶体包括白蛋白、聚葡萄糖、明胶和羟乙基淀粉，而晶体包括平衡电解质溶液、葡萄糖、生理食盐水水和乳酸林格氏液。每种製剂类别都有其独特的治疗特性和监管要求，这些都会影响临床选择、标籤要求和保质期管理。

影响采购、製造地和监管应对措施的区域趋势和战略重点（美洲、欧洲、中东、非洲、亚太地区）

区域趋势对美洲、欧洲、中东和非洲以及亚太地区的製造策略、监管互动和采购行为有着深远的影响，因为这些地区的商业环境各不相同。在美洲，一体化的医疗保健系统和中央采购组织推动了规模效益的提升，而强大的本土製造能力则帮助企业快速应对需求激增。同时，在欧洲、中东和非洲地区，不同的管理体制和采购模式意味着监管协调、本地临床证据以及与经销商的关係是实现广泛市场进入的关键。

企业策略情报揭示了领先的大容量注射剂领域关键相关人员的竞争定位、製造能力、伙伴关係模式和创新方法

大容量注射剂领域的竞争动态取决于卓越的生产製造能力、合规性、伙伴关係模式和创新速度。主要企业通常将强大的无菌生产能力与检验的包装系统结合，以满足多样化的临床需求和监管要求。契约製造和填充包装公司在扩大产能、帮助新参与企业达到品质标准以及避免重复资本投资方面发挥关键作用。

为行业领导者提供切实可行的建议，以增强注射剂护理领域的供应链韧性、优化产品系列併加速以患者为中心的交付路径。

业界领导者应采取一系列切实可行的倡议，以增强韧性、保障利润并改善患者疗效。首先，应扩大区域製造和双源采购策略，以降低贸易政策变化和物流中断带来的风险。建立检验的替代供应商以及区域填充和包装能力，既能确保生产的连续性，又能灵活调配产能以满足突发的临床需求。

透明的调查方法，明确列出了资料来源、专家咨询、检验通讯协定和分析框架，以支持报告基于证据的结论。

本报告的研究结合了结构化的原始研究和严谨的二手研究，并辅以分析三角验证和品质保证通讯协定。原始研究包括对临床医生、采购主管、生产经理和供应链专家进行深入访谈，以了解实际营运和未来发展重点。这些专家的见解与二级资讯来源（包括监管指南、技术标准和已发表的临床文献）相结合，以确保证据基础的全面性。

简洁的结论整合了对临床医生、製造商、支付方和采购团队的实际意义，以应对大容量注射剂不断变化的现实。

总之，大容量注射治疗的关键在于临床需求与运作复杂性的交会点。不断变化的医疗环境、供应链的脆弱性、包装创新以及日益严格的监管审查，共同构成了挑战，同时也带来了竞争优势。透过将临床优先事项与生产的柔软性和分销能力相结合，相关人员可以在降低风险的同时，提升患者照护水准。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依产品类型分類的大容量注射市场

  • 胶体製剂
    • 白蛋白
    • 聚葡萄糖
    • 明胶
    • 羟乙基淀粉
  • 晶体溶液
    • 平衡电解质溶液
    • 葡萄糖
    • 生理食盐水
    • 林格氏乳酸盐溶液

9. 依包装类型分類的大容量注射市场

  • 包包
  • 瓶子
    • 塑胶
    • 玻璃

第十章 以最终用户分類的大容量注射剂市场

  • 门诊治疗
  • 诊所
  • 居家医疗
  • 医院

第十一章 依应用分類的大容量注射市场

  • 血容量扩张
  • 静脉输液补充
  • 药物输送
  • 营养支持

第十二章 按分销管道分類的大容量注射剂市场

  • 离线
  • 在线的

第十三章：各区域大容量注射市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 大容量注射剂市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国大容量注射剂市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国大容量注射剂市场

第十七章 中国大容量注射剂市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories Inc.
  • Albert David Ltd.
  • Amanta Healthcare
  • B. Braun Melsungen AG
  • BAG Healthcare GmbH
  • Baxter International Inc.
  • Becton Dickinson & Co.（BD）
  • Beximco Pharmaceutical Ltd.
  • Cipla Limited
  • Cook Pharmica LLC
  • Fresenius Kabi AG
  • Grifols SA
  • ICU Medical Inc.
  • JW Life Science
  • Otsuka Pharmaceutical Co.（Otsuka Holdings Co., Ltd.）
  • Pfizer Inc.（including Hospira assets）
  • Sandoz（a spin-off of Novartis）
  • Sichuan Kelun Pharmaceutical Co., Ltd.
  • Terumo Corp.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-7A380DA7C42A

The Large Volume Parenteral Market was valued at USD 3.74 billion in 2025 and is projected to grow to USD 3.99 billion in 2026, with a CAGR of 7.74%, reaching USD 6.30 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.74 billion
Estimated Year [2026] USD 3.99 billion
Forecast Year [2032] USD 6.30 billion
CAGR (%) 7.74%

A strategic introduction to large volume parenteral therapy that frames clinical significance, supply chain intricacies, and technological regulatory evolutions shaping care delivery

Large volume parenteral therapies remain foundational to acute and chronic care pathways, providing indispensable support for fluid balance, hemodynamic stabilization, medication delivery, and nutritional supplementation. The clinical imperative is broad, spanning perioperative management, critical care resuscitation, ambulatory intravenous therapies, and long-term parenteral nutrition. Against this backdrop, the industry's operational landscape has grown more complex, driven by the interplay of clinical best practices, changing care settings, and evolving manufacturing norms.

Supply chains for large volume parenterals are characterized by precision, regulatory oversight, and a reliance on both specialized raw materials and validated aseptic manufacturing environments. At the same time, advancements in formulation, container closure systems, and delivery devices continue to influence prescribing behavior and procurement decisions. Regulatory agencies are increasingly focused on sterility assurance, stability data, and labeling that supports safe use across diverse care settings, which in turn elevates pre-market scrutiny and post-market vigilance.

Given these dynamics, stakeholders must navigate a landscape where clinical needs, product design, and regulatory expectations converge. This introduction establishes the strategic parameters that frame subsequent sections, emphasizing the need for integrated clinical, manufacturing, and commercial approaches to manage risk and seize opportunities in the large volume parenteral arena.

Identification of transformative shifts altering clinical practice, manufacturing paradigms, and supply resilience that are redefining large volume parenteral landscapes globally

The large volume parenteral arena is undergoing transformative shifts that touch clinical practice, manufacturing architecture, and commercial models. Clinically, there is an observable movement toward patient-centric care pathways that prioritize outpatient administration, shorter hospital stays, and home-based infusion solutions. This shift compels manufacturers and providers to adapt formulations, packaging formats, and instructions for use to support safe administration outside traditional acute-care settings.

Manufacturing and sourcing are also changing. Firms are investing in modular aseptic production, single-use technologies, and expanded regional manufacturing footprints to increase flexibility and reduce exposure to supply disruptions. Concurrently, sustainability considerations and circular-economy initiatives are influencing packaging choices and waste-management strategies, prompting development of lighter-weight containers and recyclable materials.

From a commercial perspective, digital tools for demand forecasting, traceability, and post-market surveillance are gaining traction. Real-time inventory visibility and quality-attribute tracking foster tighter collaboration among producers, distributors, and large health systems. Regulatory expectations are evolving in parallel, with authorities emphasizing robustness of sterility controls and transparency of raw material provenance. Collectively, these transformative shifts are redefining competitive advantage, favoring organizations that can integrate clinical insight, manufacturing agility, and data-driven supply chain resilience.

Assessment of the cumulative impact of United States tariff adjustments in 2025 on sourcing, production incentives, cost structures, and strategic supply chain reconfiguration

Recent tariff measures implemented by a major economy have produced ripple effects across procurement strategies, supplier selection, and manufacturing economics within the large volume parenteral sector. Tariff-related cost pressures have encouraged stakeholders to reassess global sourcing footprints, accelerate localization initiatives for critical components, and renegotiate supplier contracts to mitigate input-price volatility. In response, many organizations are recalibrating inventory buffers and adopting nearshoring strategies to reduce exposure to cross-border policy shifts.

These trade-policy developments have also catalyzed a reexamination of supplier relationships, prompting deeper collaboration on total landed cost modeling, quality alignment, and contractual flexibility. Manufacturers with diversified supplier bases and regional manufacturing capabilities have greater latitude to stabilize supply and protect margins. Likewise, procurement teams are increasingly leveraging long-term strategic partnerships and multi-sourcing models to maintain continuity of supply while managing incremental cost burdens.

Policy-driven cost impacts extend to downstream stakeholders as well, influencing hospital procurement cycles, pharmacy stocking strategies, and distributor pricing mechanics. As a consequence, health systems are exploring alternative clinical protocols and formulation choices where therapeutically appropriate, and manufacturers are accelerating product rationalization and packaging optimization efforts. Looking forward, trade policy will remain a decisive variable informing investment in production capacity, risk mitigation frameworks, and cross-border logistics optimization.

Actionable segmentation insights revealing how product types, end users, packaging formats, applications, and distribution channels interact to drive clinical and commercial priorities

A nuanced segmentation perspective illuminates how product attributes, care settings, packaging formats, clinical applications, and distribution pathways collectively shape procurement and clinical decisions. From the product type viewpoint, the landscape divides into colloids and crystalloids, with colloids encompassing albumin, dextrans, gelatins, and hydroxyethyl starch, and crystalloids covering balanced electrolyte solutions, dextrose, normal saline, and Ringer's lactate. Each formulation class carries distinct therapeutic profiles and regulatory considerations that influence clinical selection, labeling requirements, and shelf-life management.

End-user segmentation further refines demand patterns across ambulatory care, clinics, home care, and hospitals. Hospitals remain centers for acute resuscitation and complex parenteral nutrition, while ambulatory and home care settings are driving demand for formulations and packaging that support safe administration outside institutional walls. Packaging choices-bags, glass bottles, and plastic bottles, with bags subdivided into flexible plastic pouches and plastic bags-play a pivotal role in logistics, administration technique, and waste handling. Flexible pouches, for example, enable lighter transport weight and reduced cold-chain volume, whereas glass bottles can be preferred for certain stability requirements.

Application-driven segmentation differentiates needs for blood volume expansion, fluid replacement, medication delivery, and nutritional support, the latter of which spans partial parenteral nutrition and total parenteral nutrition. Distribution channels including hospital pharmacies, online pharmacies, and retail pharmacies determine accessibility, ordering cadence, and fulfillment complexity. Integrating these segmentation lenses reveals actionable implications for product design, clinical guidance, and distribution strategies, and underscores the need for tailored commercialization plans aligned with specific end-user workflows and regulatory constraints.

Regional dynamics and strategic priorities across Americas, Europe, Middle East & Africa, and Asia-Pacific that shape procurement, manufacturing footprints, and regulatory interactions

Regional dynamics exert profound influence on manufacturing strategy, regulatory engagement, and procurement behavior across the continentally distinct operating environments of Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, integrated healthcare systems and centralized purchasing entities often drive scale efficiencies, while strong domestic manufacturing capacity supports rapid response to demand surges. Conversely, Europe, Middle East & Africa features a mosaic of regulatory regimes and procurement models, which increases the importance of regulatory harmonization, localized clinical evidence, and distributor relationships to achieve broad market access.

The Asia-Pacific region combines a mix of large domestic manufacturers, rapidly evolving regulatory frameworks, and growing investment in local production capabilities. This environment encourages collaboration between multinational players and regional partners to tailor formulations and packaging that meet local clinical practices and supply chain realities. Across all regions, variations in reimbursement mechanisms, hospital procurement cycles, and logistics infrastructure shape how products are introduced, stocked, and administered.

Given these regional distinctions, successful strategies involve aligning manufacturing footprints with regional demand profiles, engaging early with regulators to address stability and sterility expectations, and designing distribution models that reflect local procurement behaviors. Cross-region comparisons reveal opportunities to leverage best practices in quality assurance, clinical education, and supply chain digitization to build resilient, regionally attuned operations.

Corporate strategic intelligence highlighting competitive positioning, manufacturing capabilities, partnership models, and innovation approaches among leading large volume parenteral stakeholders

Competitive dynamics in the large volume parenteral space are driven by a combination of manufacturing excellence, regulatory compliance, partnership models, and innovation velocity. Leading players typically combine robust aseptic manufacturing capabilities with validated packaging systems, enabling them to meet diverse clinical needs and regulatory expectations. Contract manufacturing and fill-finish specialists play a central role in scaling capacity and enabling market entrants to meet quality thresholds without duplicative capital investment.

Strategic collaborations between formulation specialists, packagers, and distribution partners accelerate time-to-clinic for complex nutritional and medication-delivery products. Companies that invest in end-to-end traceability, serialization, and cold-chain monitoring gain a competitive edge in supply assurance and customer service. At the same time, organizations that integrate clinical affairs and real-world evidence generation into commercial plans are better positioned to influence institutional formularies and protocol adoption.

Operational excellence is complemented by targeted innovation, such as optimization of container closure systems for reduced extractables and leachables, advancement of preservative-free formulations, and development of dosing-friendly formats for ambulatory administration. Collectively, these capabilities define competitive positioning and determine which firms can most effectively respond to evolving clinician preferences, regulatory expectations, and procurement priorities.

Actionable recommendations for industry leaders to strengthen supply resilience, optimize product portfolios, and accelerate patient-centric delivery pathways in parenteral care

Industry leaders should pursue a set of pragmatic actions to strengthen resilience, protect margins, and enhance patient outcomes. First, expand regional manufacturing and dual-sourcing strategies to reduce exposure to trade-policy shifts and logistics disruptions. Establishing validated alternative suppliers and regional fill-finish capacity supports continuity while allowing for responsive allocation of production to meet emergent clinical demand.

Second, prioritize packaging optimization that balances clinical usability, supply chain efficiency, and environmental stewardship. Transitioning to lightweight, recyclable formats and flexible pouch systems where clinically appropriate reduces transportation costs and waste volumes, while maintaining compatibility with bedside administration workflows.

Third, align product portfolios with evolving care settings by developing formulations and administration-ready presentations that facilitate safe use in ambulatory and home care environments. Coupling product design with clinician education and digital adherence tools increases acceptance and supports protocol shifts.

Finally, invest in advanced supply chain visibility and predictive analytics to enable real-time decision-making, proactive risk mitigation, and improved inventory management. These investments should be complemented by stronger partnerships between manufacturers, distributors, and large health systems to create shared accountability for supply continuity and quality outcomes.

Transparent research methodology describing data sources, expert engagement, validation protocols, and analytic frameworks underpinning the report's evidence-based conclusions

The research underpinning this report combines a structured blend of primary engagement and rigorous secondary investigation, complemented by analytic triangulation and quality assurance protocols. Primary inputs included in-depth interviews with clinicians, procurement leaders, manufacturing heads, and supply chain specialists to capture operational realities and forward-looking priorities. These expert perspectives were synthesized with secondary sources such as regulatory guidance, technical standards, and published clinical literature to ensure a comprehensive evidentiary base.

Analytical methods included thematic coding of qualitative interviews, supply chain risk mapping, and comparative assessment of manufacturing and packaging technologies. Findings were validated through iterative expert review sessions to reconcile divergent viewpoints and confirm practical relevance. Data integrity procedures encompassed source verification, cross-referencing of regulatory documents, and internal consistency checks across product, application, and distribution analyses.

Together, these methodological steps ensured that conclusions are grounded in practitioner experience, supported by documented standards, and stress-tested against alternative scenarios. Transparency in these methods enables stakeholders to assess the reliability of insights and to adapt analytic approaches for their own internal planning and validation exercises.

Concise conclusion synthesizing practical implications for clinicians, manufacturers, payers, and procurement teams to navigate evolving large volume parenteral realities

In summary, large volume parenteral care occupies a critical intersection of clinical necessity and operational complexity. The confluence of changing care settings, supply chain sensitivities, packaging innovation, and regulatory scrutiny creates both challenges and avenues for competitive differentiation. By integrating clinical priorities with manufacturing flexibility and distribution intelligence, stakeholders can reduce risk while enhancing patient care delivery.

Strategic emphasis on regional manufacturing alignment, packaging evolution, and multi-channel distribution will be central to building resilient supply networks. Concurrent investment in digital tools for traceability, predictive inventory management, and post-market surveillance will further strengthen system responsiveness. Importantly, clinical and commercial leaders should pursue collaborative models that align incentives across manufacturers, distributors, and health systems to ensure reliable access to high-quality large volume parenteral products.

This conclusion underscores that adaptive, integrated strategies-rooted in operational excellence and clinical alignment-are essential for navigating the evolving landscape and sustaining long-term performance in parenteral therapies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Large Volume Parenteral Market, by Product Type

  • 8.1. Colloids
    • 8.1.1. Albumin
    • 8.1.2. Dextrans
    • 8.1.3. Gelatins
    • 8.1.4. Hydroxyethyl Starch
  • 8.2. Crystalloids
    • 8.2.1. Balanced Electrolyte Solutions
    • 8.2.2. Dextrose
    • 8.2.3. Normal Saline
    • 8.2.4. Ringer's Lactate

9. Large Volume Parenteral Market, by Packaging

  • 9.1. Bags
  • 9.2. Bottles
    • 9.2.1. Plastic
    • 9.2.2. Glass

10. Large Volume Parenteral Market, by End User

  • 10.1. Ambulatory Care
  • 10.2. Clinics
  • 10.3. Home Care
  • 10.4. Hospitals

11. Large Volume Parenteral Market, by Application

  • 11.1. Blood Volume Expansion
  • 11.2. Fluid Replacement
  • 11.3. Medication Delivery
  • 11.4. Nutritional Support

12. Large Volume Parenteral Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Large Volume Parenteral Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Large Volume Parenteral Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Large Volume Parenteral Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Large Volume Parenteral Market

17. China Large Volume Parenteral Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories Inc.
  • 18.6. Albert David Ltd.
  • 18.7. Amanta Healthcare
  • 18.8. B. Braun Melsungen AG
  • 18.9. BAG Healthcare GmbH
  • 18.10. Baxter International Inc.
  • 18.11. Becton Dickinson & Co. (BD)
  • 18.12. Beximco Pharmaceutical Ltd.
  • 18.13. Cipla Limited
  • 18.14. Cook Pharmica LLC
  • 18.15. Fresenius Kabi AG
  • 18.16. Grifols S.A.
  • 18.17. ICU Medical Inc.
  • 18.18. JW Life Science
  • 18.19. Otsuka Pharmaceutical Co. (Otsuka Holdings Co., Ltd.)
  • 18.20. Pfizer Inc. (including Hospira assets)
  • 18.21. Sandoz (a spin-off of Novartis)
  • 18.22. Sichuan Kelun Pharmaceutical Co., Ltd.
  • 18.23. Terumo Corp.
  • 18.24. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LARGE VOLUME PARENTERAL MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL LARGE VOLUME PARENTERAL MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY PACKAGING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES LARGE VOLUME PARENTERAL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA LARGE VOLUME PARENTERAL MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY COLLOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY COLLOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY COLLOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY COLLOIDS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY ALBUMIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY ALBUMIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY ALBUMIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY DEXTRANS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY DEXTRANS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY DEXTRANS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY GELATINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY GELATINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY GELATINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY HYDROXYETHYL STARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY HYDROXYETHYL STARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY HYDROXYETHYL STARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY CRYSTALLOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY CRYSTALLOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY CRYSTALLOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY CRYSTALLOIDS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY BALANCED ELECTROLYTE SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY BALANCED ELECTROLYTE SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY BALANCED ELECTROLYTE SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY DEXTROSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY DEXTROSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY DEXTROSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY NORMAL SALINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY NORMAL SALINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY NORMAL SALINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY RINGER'S LACTATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY RINGER'S LACTATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY RINGER'S LACTATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY BAGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY BAGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY BAGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY BOTTLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY BOTTLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY BOTTLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY BOTTLES, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY PLASTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY PLASTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY PLASTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY GLASS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY GLASS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY GLASS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY BLOOD VOLUME EXPANSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY BLOOD VOLUME EXPANSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY BLOOD VOLUME EXPANSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY FLUID REPLACEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY FLUID REPLACEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY FLUID REPLACEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY MEDICATION DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY MEDICATION DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY MEDICATION DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY NUTRITIONAL SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY NUTRITIONAL SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY NUTRITIONAL SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS LARGE VOLUME PARENTERAL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS LARGE VOLUME PARENTERAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS LARGE VOLUME PARENTERAL MARKET SIZE, BY COLLOIDS, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS LARGE VOLUME PARENTERAL MARKET SIZE, BY CRYSTALLOIDS, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS LARGE VOLUME PARENTERAL MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS LARGE VOLUME PARENTERAL MARKET SIZE, BY BOTTLES, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS LARGE VOLUME PARENTERAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS LARGE VOLUME PARENTERAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS LARGE VOLUME PARENTERAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA LARGE VOLUME PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA LARGE VOLUME PARENTERAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA LARGE VOLUME PARENTERAL MARKET SIZE, BY COLLOIDS, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA LARGE VOLUME PARENTERAL MARKET SIZE, BY CRYSTALLOIDS, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA LARGE VOLUME PARENTERAL MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA LARGE VOLUME PARENTERAL MARKET SIZE, BY BOTTLES, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA LARGE VOLUME PARENTERAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA LARGE VOLUME PARENTERAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA LARGE VOLUME PARENTERAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA LARGE VOLUME PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA LARGE VOLUME PARENTERAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA LARGE VOLUME PARENTERAL MARKET SIZE, BY COLLOIDS, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA LARGE VOLUME PARENTERAL MARKET SIZE, BY CRYSTALLOIDS, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA LARGE VOLUME PARENTERAL MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA LARGE VOLUME PARENTERAL MARKET SIZE, BY BOTTLES, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA LARGE VOLUME PARENTERAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA LARGE VOLUME PARENTERAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA LARGE VOLUME PARENTERAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA LARGE VOLUME PARENTERAL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA LARGE VOLUME PARENTERAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA LARGE VOLUME PARENTERAL MARKET SIZE, BY COLLOIDS, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA LARGE VOLUME PARENTERAL MARKET SIZE, BY CRYSTALLOIDS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA LARGE VOLUME PARENTERAL MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA LARGE VOLUME PARENTERAL MARKET SIZE, BY BOTTLES, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA LARGE VOLUME PARENTERAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA LARGE VOLUME PARENTERAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA LARGE VOLUME PARENTERAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE LARGE VOLUME PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE LARGE VOLUME PARENTERAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE LARGE VOLUME PARENTERAL MARKET SIZE, BY COLLOIDS, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE LARGE VOLUME PARENTERAL MARKET SIZE, BY CRYSTALLOIDS, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE LARGE VOLUME PARENTERAL MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE LARGE VOLUME PARENTERAL MARKET SIZE, BY BOTTLES, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE LARGE VOLUME PARENTERAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE LARGE VOLUME PARENTERAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE LARGE VOLUME PARENTERAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST LARGE VOLUME PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST LARGE VOLUME PARENTERAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST LARGE VOLUME PARENTERAL MARKET SIZE, BY COLLOIDS, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST LARGE VOLUME PARENTERAL MARKET SIZE, BY CRYSTALLOIDS, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST LARGE VOLUME PARENTERAL MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST LARGE VOLUME PARENTERAL MARKET SIZE, BY BOTTLES, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST LARGE VOLUME PARENTERAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST LARGE VOLUME PARENTERAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST LARGE VOLUME PARENTERAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA LARGE VOLUME PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA LARGE VOLUME PARENTERAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA LARGE VOLUME PARENTERAL MARKET SIZE, BY COLLOIDS, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA LARGE VOLUME PARENTERAL MARKET SIZE, BY CRYSTALLOIDS, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA LARGE VOLUME PARENTERAL MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA LARGE VOLUME PARENTERAL MARKET SIZE, BY BOTTLES, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA LARGE VOLUME PARENTERAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA LARGE VOLUME PARENTERAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA LARGE VOLUME PARENTERAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC LARGE VOLUME PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC LARGE VOLUME PARENTERAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC LARGE VOLUME PARENTERAL MARKET SIZE, BY COLLOIDS, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC LARGE VOLUME PARENTERAL MARKET SIZE, BY CRYSTALLOIDS, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC LARGE VOLUME PARENTERAL MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC LARGE VOLUME PARENTERAL MARKET SIZE, BY BOTTLES, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC LARGE VOLUME PARENTERAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC LARGE VOLUME PARENTERAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC LARGE VOLUME PARENTERAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN LARGE VOLUME PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN LARGE VOLUME PARENTERAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN LARGE VOLUME PARENTERAL MARKET SIZE, BY COLLOIDS, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN LARGE VOLUME PARENTERAL MARKET SIZE, BY CRYSTALLOIDS, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN LARGE VOLUME PARENTERAL MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN LARGE VOLUME PARENTERAL MARKET SIZE, BY BOTTLES, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN LARGE VOLUME PARENTERAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN LARGE VOLUME PARENTERAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN LARGE VOLUME PARENTERAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. GCC LARGE VOLUME PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GCC LARGE VOLUME PARENTERAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. GCC LARGE VOLUME PARENTERAL MARKET SIZE, BY COLLOIDS, 2018-2032 (USD MILLION)
  • TABLE 168. GCC LARGE VOLUME PARENTERAL MARKET SIZE, BY CRYSTALLOIDS, 2018-2032 (USD MILLION)
  • TABLE 169. GCC LARGE VOLUME PARENTERAL MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 170. GCC LARGE VOLUME PARENTERAL MARKET SIZE, BY BOTTLES, 2018-2032 (USD MILLION)
  • TABLE 171. GCC LARGE VOLUME PARENTERAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. GCC LARGE VOLUME PARENTERAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. GCC LARGE VOLUME PARENTERAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION LARGE VOLUME PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION LARGE VOLUME PARENTERAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION LARGE VOLUME PARENTERAL MARKET SIZE, BY COLLOIDS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION LARGE VOLUME PARENTERAL MARKET SIZE, BY CRYSTALLOIDS, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION LARGE VOLUME PARENTERAL MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION LARGE VOLUME PARENTERAL MARKET SIZE, BY BOTTLES, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION LARGE VOLUME PARENTERAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION LARGE VOLUME PARENTERAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION LARGE VOLUME PARENTERAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS LARGE VOLUME PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS LARGE VOLUME PARENTERAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS LARGE VOLUME PARENTERAL MARKET SIZE, BY COLLOIDS, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS LARGE VOLUME PARENTERAL MARKET SIZE, BY CRYSTALLOIDS, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS LARGE VOLUME PARENTERAL MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS LARGE VOLUME PARENTERAL MARKET SIZE, BY BOTTLES, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS LARGE VOLUME PARENTERAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS LARGE VOLUME PARENTERAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS LARGE VOLUME PARENTERAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. G7 LARGE VOLUME PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. G7 LARGE VOLUME PARENTERAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. G7 LARGE VOLUME PARENTERAL MARKET SIZE, BY COLLOIDS, 2018-2032 (USD MILLION)
  • TABLE 195. G7 LARGE VOLUME PARENTERAL MARKET SIZE, BY CRYSTALLOIDS, 2018-2032 (USD MILLION)
  • TABLE 196. G7 LARGE VOLUME PARENTERAL MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 197. G7 LARGE VOLUME PARENTERAL MARKET SIZE, BY BOTTLES, 2018-2032 (USD MILLION)
  • TABLE 198. G7 LARGE VOLUME PARENTERAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. G7 LARGE VOLUME PARENTERAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 200. G7 LARGE VOLUME PARENTERAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. NATO LARGE VOLUME PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. NATO LARGE VOLUME PARENTERAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. NATO LARGE VOLUME PARENTERAL MARKET SIZE, BY COLLOIDS, 2018-2032 (USD MILLION)
  • TABLE 204. NATO LARGE VOLUME PARENTERAL MARKET SIZE, BY CRYSTALLOIDS, 2018-2032 (USD MILLION)
  • TABLE 205. NATO LARGE VOLUME PARENTERAL MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 206. NATO LARGE VOLUME PARENTERAL MARKET SIZE, BY BOTTLES, 2018-2032 (USD MILLION)
  • TABLE 207. NATO LARGE VOLUME PARENTERAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. NATO LARGE VOLUME PARENTERAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 209. NATO LARGE VOLUME PARENTERAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES LARGE VOLUME PARENTERAL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES LARGE VOLUME PARENTERAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES LARGE VOLUME PARENTERAL MARKET SIZE, BY COLLOIDS, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES LARGE VOLUME PARENTERAL MARKET SIZE, BY CRYSTALLOIDS, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES LARGE VOLUME PARENTERAL MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES LARGE VOLUME PARENTERAL MARKET SIZE, BY BOTTLES, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES LARGE VOLUME PARENTERAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES LARGE VOLUME PARENTERAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES LARGE VOLUME PARENTERAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA LARGE VOLUME PARENTERAL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA LARGE VOLUME PARENTERAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA LARGE VOLUME PARENTERAL MARKET SIZE, BY COLLOIDS, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA LARGE VOLUME PARENTERAL MARKET SIZE, BY CRYSTALLOIDS, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA LARGE VOLUME PARENTERAL MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA LARGE VOLUME PARENTERAL MARKET SIZE, BY BOTTLES, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA LARGE VOLUME PARENTERAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA LARGE VOLUME PARENTERAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA LARGE VOLUME PARENTERAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)